SAB Biotherapeutics IncNASDAQ:SABS
- LAST PRICE4.0400
- TODAY'S CHANGE (%)0.1600 (4.1237%)
- Bid / Lots3.8100/ 2
- Ask / Lots4.5000/ 1
- Open / Previous Close3.8800 / 3.8800
- Day Range
- 52 Week Range
- Volume83,037
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SABS |
|---|---|---|
| 09:32 ET | 1283 | 3.9169 |
| 09:33 ET | 1000 | 3.8 |
| 09:35 ET | 551 | 3.91 |
| 09:39 ET | 792 | 3.85 |
| 09:44 ET | 400 | 3.895 |
| 09:46 ET | 100 | 3.9 |
| 10:02 ET | 1000 | 3.8167 |
| 10:04 ET | 200 | 3.81 |
| 10:06 ET | 204 | 3.88 |
| 10:08 ET | 550 | 3.9026 |
| 10:24 ET | 100 | 3.88 |
| 10:36 ET | 1367 | 3.9399 |
| 10:38 ET | 105 | 3.94 |
| 10:45 ET | 2502 | 4.02 |
| 10:49 ET | 1638 | 4.005 |
| 10:54 ET | 375 | 4.0968 |
| 10:58 ET | 12631 | 4.19 |
| 11:00 ET | 1000 | 4.17 |
| 11:03 ET | 1115 | 4.3127 |
| 11:05 ET | 500 | 4.08 |
| 11:23 ET | 300 | 4.08 |
| 11:25 ET | 1576 | 4.01 |
| 11:36 ET | 400 | 4.15 |
| 11:43 ET | 1000 | 4 |
| 11:45 ET | 100 | 4.08 |
| 11:57 ET | 844 | 4.01 |
| 11:59 ET | 250 | 4.0538 |
| 12:01 ET | 784 | 4.05 |
| 12:03 ET | 100 | 4.055 |
| 12:12 ET | 1250 | 4.0101 |
| 12:14 ET | 499 | 4.01 |
| 12:26 ET | 5721 | 4.1 |
| 12:28 ET | 400 | 4.2 |
| 12:35 ET | 601 | 4.17 |
| 12:39 ET | 150 | 4.1382 |
| 12:53 ET | 242 | 4.18 |
| 01:09 ET | 600 | 4.1915 |
| 01:11 ET | 100 | 4.15 |
| 01:24 ET | 5328 | 4.23 |
| 01:26 ET | 5030 | 4.3699 |
| 01:29 ET | 100 | 4.13 |
| 01:42 ET | 4200 | 4.2093 |
| 01:45 ET | 2000 | 4.2101 |
| 01:51 ET | 400 | 4.262 |
| 01:54 ET | 300 | 4.28 |
| 02:12 ET | 474 | 4.34 |
| 02:14 ET | 100 | 4.319 |
| 02:16 ET | 100 | 4.22 |
| 02:23 ET | 300 | 4.34 |
| 02:27 ET | 300 | 4.15 |
| 02:32 ET | 742 | 4.01 |
| 02:34 ET | 1457 | 4 |
| 02:36 ET | 592 | 4 |
| 02:50 ET | 5600 | 3.945 |
| 02:52 ET | 100 | 4.17 |
| 02:54 ET | 641 | 3.89 |
| 03:01 ET | 100 | 3.94 |
| 03:08 ET | 350 | 4.0516 |
| 03:15 ET | 563 | 4.0941 |
| 03:17 ET | 200 | 4.0106 |
| 03:42 ET | 500 | 4.16 |
| 03:55 ET | 4096 | 4.16 |
| 03:57 ET | 400 | 4.125 |
| 04:00 ET | 924 | 4.04 |
Oct 31, 2024
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference, from 7:00AM ET on Thursday Oct 31, 2024 by Dow Jones
7:00AM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 9, 2024
DJ SAB Biotherapeutics Initiated at Buy by Craig-Hallum, from 8:39AM ET on Wednesday Oct 09, 2024 by Dow Jones
8:39AM ET on Wednesday Oct 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
SAB Biotherapeutics Inc | 35.8M | -0.7x | --- |
Lumos Pharma Inc | 37.8M | -1.0x | --- |
Lipocine Inc | 32.5M | -3.8x | --- |
Dyadic International Inc | 31.2M | -3.9x | --- |
Marker Therapeutics Inc | 32.7M | -3.0x | --- |
Nuo Therapeutics Inc | 36.1M | -12.7x | --- |
Company Information
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.
Contact Information
- Headquarters
- 777 W 41St St, Suite 401MIAMI BEACH, FL, United States 33140
- Phone
- 305-845-2813
- Fax
- 302-636-5454
Executives
- Executive Chairman of the Board, Chief Executive Officer
- Samuel Reich
- President, Director
- Eddie Sullivan
- Non-Executive Independent Vice Chairman of the Board
- David Link
- Chief Financial Officer
- Lucy To
- Chief Operating Officer
- Christoph Bausch
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $35.8M |
|---|---|
Revenue (TTM) | $2.8M |
Shares Outstanding | 9.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.63 |
EPS | $-5.69 |
Book Value | $6.21 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 12.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,647.03% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
